Pfizer Italia S.r.l.

Pharmacia & Upjohn

Pharmacia Italia S.p.a.

Francesco Angelucci

Maria Gabriella Brasca

Barbara Salom

William John Trigg

Edward Andrew Boyd

Frederick Arthur Brookfield

Jonathan Anthony Larard

Patrizia Giordano

Matteo D'anello

Katia Martina

Dania Tesei

Matteo D'Anello

Carlo Battistini

Alberto Bardelli

Paolo Comoglio

Fabio Corradi

Sabrina De Rosa

William John Evotec Oai Trigg

Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.

Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors

Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them

Pyrrolo[2,3-B]pyridine derivatives active as kinase inhibitors

The present invention relates to peptides and peptidomimetic compounds and pharmaceutical compositions containing them as useful pharmacological agents in the control or treatment of proliferative diseases such as cancer, against tumor growing and/or tumoral metastasis, and psoriasis and in the control or treatment of inflammatory, allergic, autoimmune, viral, and cardiovascular diseases. These new compounds have the unique property to inhibit the recognition of several phosphotyrosine containing motifs within all the cellular receptors and cytosolic transducers by a wide spectrum of SH2 domains contained in cytosolic transducers and other effector proteins laying along different pathways of the signal transduction process and with a particularly high affinity for the SH2 domain of the adaptor transducer Grb2, a key element along the pathway to mitogenesis and motogenesis, this last activity leading to invasiveness and to metastasis. The invention also relates to methods for production of the compounds and methods of treatment employing the compounds.

Peptide antagonists of cellular mitogenesis and motogenesis and their therapeutic use

Growing community of inventors

Cuneo, Italy

Patrizia Giordano